Silexion Therapeutics Reports Strong Preclinical Tumor Inhibition With SIL204 in KRAS-Mutated Cancers
I'm PortAI, I can summarize articles.
Silexion Therapeutics Corp. reported strong preclinical results for its RNAi therapy, SIL204, which showed significant tumor inhibition in KRAS-mutated cancers, including pancreatic, colorectal, and lung cancers. The findings, achieved in 2025, are set to be followed by human clinical trials in the first half of 2026. The company also received positive feedback from Germany’s BfArM on its Phase 2/3 trial design for SIL204 in locally advanced pancreatic cancer.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments